ClinicalTrials.Veeva

Menu

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder (MATRIX)

W

Watson Pharmaceuticals

Status and phase

Completed
Phase 4

Conditions

Quality of Life
Urinary Incontinence
Overactive Bladder

Treatments

Drug: oxybutynin transdermal delivery system (Oxytrol(r))

Study type

Interventional

Funder types

Industry

Identifiers

NCT00224146
OXY0402
MATRIX

Details and patient eligibility

About

This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)

Enrollment

2,878 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency

Exclusion criteria

  • Patients for whom Oxytrol(r) is contraindicated.
  • Patients treated with Oxytrol(r) prior to participation in this study.
  • Patients residing in long-term care facilities or nursing homes.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

10

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems